<DOC>
	<DOCNO>NCT02546219</DOCNO>
	<brief_summary>The overall objective preclinical study investigator mechanistic understanding role α4β7 mucosal addressin cell adhesion molecule ( MAdCAM-1 ) pathway play mediate eosinophil recruitment EoE . To accomplish , investigator aim ( 1 ) determine baseline dynamic pattern α4β7 integrin expression circulate tissue eosinophil EoE set non-EoE esophageal eosinophilia ( e.g. , reflux esophagitis ) ( 2 ) determine complete profile eosinophil integrin molecule may play role active EoE .</brief_summary>
	<brief_title>a4b7 Integrin Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>1 . Able give write informed consent 2 . Male female patient age 1865 year time screen 3 . Confirmed active EoE screening within 8 week prior baseline visit , define esophageal mucosal eosinophils ≥15 per high power field ( HPF , 400X magnification ) despite least 4 week proton pump inhibitor ( PPI ) therapy omeprazole 20 mg twice daily equivalent . update 14APR2015 Page 8 19 4 . Within week prior dosing , patient one follow symptom moderate , bad , severity : dysphagia , vomit , regurgitation , abdominal pain , chest pain/heartburn . 5 . Maintained stabilized diet least 6 week prior screen course study ; stable diet define initiation single multiple elimination diet reintroduction previously eliminate food group . 6 . Willing able comply clinic visit studyrelated procedure 7 . Able understand complete studyrelated questionnaire 1 . Another disorder cause esophageal eosinophilia ( e.g. , hypereosinophilic syndrome , ChurgStrauss , parasitic infection ) 2 . History abnormal gastric duodenal biopsy document GI disorder EoE ( e.g. , celiac disease , Crohn 's disease H. pylori infection ) 3 . History follow GI surgery : fundoplication , gastric surgery surgery esophageal atresia 4 . Use systemic immunosuppressive immunomodulating agent ( oral prednisone , antiimmunoglobulin E ( IgE ) monoclonal antibody ( mAb ) , methotrexate , cyclosporine , INFα , antiTNF ) within six month prior study entry . 5 . A stricture endoscopy prevents passage endoscope 6 . Participation investigational drug device study within 30 day prior study entry . 7 . Female subject pregnant nursing . 8 . Chronic infection HIV , hepatitis B C , active mycobacterial ( TB ) fungal infection . 9 . Neoplasm history malignancy precede 5 year . 10 . Concurrent infection disease may preclude assessment eosinophilic esophagitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>eosinophilic esophagitis</keyword>
	<keyword>EoE</keyword>
	<keyword>integrins</keyword>
</DOC>